Alveolus Bio Inc. Company Research Report

Company Overview

• Name: Alveolus Bio Inc.

• Mission: The company is on a mission to disrupt the standard of care for chronic and infectious lung diseases, focusing on pioneering biotherapeutic delivery for prevention and treatment of chronic lung disease.

• Founded By: The company originated in Dr. Vivek Lal’s Pulmonary Microbiome Lab and Dr. Amit Gaggar’s Program in Lung Protease and Matrix Biology at the University of Alabama at Birmingham (UAB).

• Key People:

• C Vivek Lal MD FAAP, Founder & CSO

• Amit Gaggar MD PhD, Chief Medical Officer

• Gaurav Mehta MBA, CEO

• Andrew O'Connor MS MBA, CMC Advisor

• Theodora Nicola MD PhD MBA, Director of Research

• Nancy Wenger, Associate Director

• Headquarters:

• 1500 1st Ave N, Birmingham, AL 35203

• 1 Broadway, Cambridge, MA 02142

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Alveolus Bio is known for pioneering breakthrough FDA-approved therapeutics for lung diseases through its proprietary resMIT platform, which delivers safe, targeted bacteria directly to the lungs.

Products

Overview

Alveolus Bio focuses on developing inhaled live biotherapeutics, targeting diseases such as Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE).

Products and Features:

1. Idiopathic Pulmonary Fibrosis (IPF):

• A specialized program focusing on this orphan disease aiming to address fibroblast dysfunction.

• Key Features: Uses inhaled delivery to target lung tissues directly.

2. Chronic Obstructive Pulmonary Disease (COPD):

• Targeted for 15 million patients in the US.

• Key Features: Addresses neutrophilic inflammation to improve respiratory function.

3. Non-Cystic Fibrosis Bronchiectasis (NCFBE):

• Focused on rare disease management.

• Key Features: Similar inhaled biotherapeutic approach to mitigate lung tissue inflammation.

Recent Developments

• New Products Launched: No information is available

• New Features Added to Existing Products: No information is available

• New Partnerships: Alveolus Bio is open to partnership opportunities but specific partnerships are not detailed.

Research and Infrastructure

• Research Foundation: Alveolus Bio is built on a vast local infrastructure and notable personnel to drive drug discovery, preclinical development, and to support a range of respiratory diseases.

• Key Research Contributions:

• "Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD" (2021) highlighted the impacts of early life events on chronic respiratory diseases.

• Studies focused on microbial signatures and their influences on severe bronchopulmonary dysplasia development.

• Analysis of pulmonary microbiome alterations related to respiratory disorders.

Conclusion

Alveolus Bio Inc. stands at the forefront of integrated pulmonary and microbiome science research, with a strong emphasis on developing innovative solutions for respiratory diseases. Through collaboration and strategic development, it aims to revolutionize respiratory disease management with a strong team of interdisciplinary experts.

(Note: Fields such as specific financial figures and new products or partnerships are noted as "No information is available". This reflects the data provided and maintains the report's professional structure.)